PMEL and sarcoma: The absence of lineage-specific markers, including EMA, CD34, CD31, myogenic markers (MyoD1, myogenin), melanocytic markers (HMB-45), and lymphoid markers (CD45), helped exclude alternative diagnoses such as sarcomas and hematologic malignancies.